Breaking News

Charles River Laboratories Completes the Acquisition of SAMDI Tech

Strengthens drug discovery support services.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Charles River Laboratories International has acquired SAMDI Tech for $50 million.   The two companies have been partners since 2018.   “The acquisition of SAMDI Tech’s cutting-edge, high-throughput screening technology further strengthens Charles River’s drug discovery capabilities and enhances our unique ability to serve as an integrated partner to support our clients’ early-stage research,” said James Foster, chairman, president and CEO Charles River Laboratories. “SAMDI Tech’s platform co...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters